  Conventional drugs work, as a rule, by inhibiting the enzymatic activity of
specific proteins, capping their active site. In this paper we present a model
of non- conventional drug design based on the inhibiting effects small peptides
obtained from segments of the protein itself have on the folding ability of the
system. Such peptides attach to the newly expressed (unfolded) protein and
inhibit its folding, inhibition which cannot be avoided but through mutations
which in any case denaturate the enzyme. These peptides, or their mimetic
molecules, can be used as effective alternative drugs to those already
available, displaying the advantage of not suffering from the upraise of
resistence.
